Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon MRI in Pulmonary Hypertension
NCT04991454Phase 2Recruiting
- Start
- Sep 2021
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of hyperpolarized xenon gas in pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) (2 arms). Primary endpoints: Pulmonary vascular remodeling at 5 years and Red Blood Cell Signal from Xenon MRI at 5 years. Started Sep 2021; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
pulmonary hypertension (PH)pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04991454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991454.